DEFENCE THERAPEUTICS INC
Commented by Stefan Feulner on August 2nd, 2023 | 09:15 CEST
Well positioned for the future - BioNTech, Defence Therapeutics, Sanofi
There is currently a lot of movement in the capital-intensive biotech sector. After second-tier companies, in particular, were hit hard by the effects of tighter monetary policy last year and at times traded below their cash levels, many are now considered hot takeover candidates thanks to their innovative technologies. The well-heeled pharma giants must act to avoid missing out on future blockbusters.
Read
Commented by Juliane Zielonka on July 13th, 2023 | 07:40 CEST
Defence Therapeutics, Bayer AG, Rheinmetall: Patents, price jump and billions of euros
The global biotechnology market is estimated to grow at a CAGR of 12.8% from 2023 to 2030. This has prompted Defence Therapeutics to secure numerous patents for their innovative platform technology ACCUM™. The platform is the linchpin for therapies in the fight against globally prevalent cancers such as lung, breast, and pancreatic cancer. Defence Therapeutics focuses on strengthening the body's immune system to defend against evil invaders. Cancer is also a topic at Bayer AG. The share price jumps as rumors circulate that the Group intends to divest its agricultural division - including Monsanto and the weedkiller suspected of causing cancer. Rheinmetall can report a further plus. Both the German and Dutch armies are ordering airborne vehicles worth billions. Whether these orders are intended solely for Ukraine will become clearer as the latest news unfolds regarding NATO's activities.
Read
Commented by Armin Schulz on July 6th, 2023 | 07:55 CEST
TUI, Defence Therapeutics, Plug Power - Who has the potential for a rally?
The search for stocks with the potential for a rally is an exciting and promising task for investors. There are several approaches and strategies to find appropriate stocks. One commonly used approach is fundamental analysis, which examines a company's financial health, business models, growth prospects and other fundamental factors. Solid fundamental analysis can help identify companies with strong potential for future growth. We have chosen three companies with strong upside potential.
Read
Commented by André Will-Laudien on June 30th, 2023 | 07:30 CEST
Doublers are possible! Bayer, Defence Therapeutics, BioNTech, Valneva - It is hard to believe!
In 2022, a total of 19.5 million people received the shocking diagnosis of "cancer". Current trends, unfortunately, suggest that this number will continue to rise in the coming years. However, thanks to growing research successes, there is hope that biotechnology will significantly increase the chances of survival for those affected. It is a matter of developing suitable active substances and launching modern therapies. mRNA technology has recently made a name for itself in cancer prevention. Innovative biotech companies are back on the radar of risk-conscious investors. We are on the lookout for doubling potential.
Read
Commented by Stefan Feulner on June 26th, 2023 | 08:50 CEST
Best conditions for a summer rally - Defence Therapeutics, SMA Solar, Rheinmetall
The German stock market reflects the current weather situation - bright to cloudy, with occasional dark clouds moving in, bringing thunderstorms and heavy rain. In the past few days, lightning struck companies such as Helma Eigenheimbau, Siemens Energy and Lanxess, which was reflected in price losses of well over 10%. Other companies were spared from the storm front and should continue to enjoy their place in the sun due to the positive news.
Read
Commented by Fabian Lorenz on June 14th, 2023 | 07:00 CEST
Evotec, Morphosys, Defence Therapeutics: Strong biotech stocks
When thinking of strong biotech stocks in recent years, BioNTech likely came to mind initially. With the successful development of the COVID-19 vaccine, the Mainz-based company advanced to become the new industry high-flyer. But in the meantime, the Company has come back to reality. The coffers are bulging, but vaccine revenues are falling, and the development of the cancer pipeline will still take several years. Therefore, Evotec and Morphosys are currently celebrating a comeback. Analysts are hailing Evotec as the "Tesla of biotech," and price targets are rising. The Morphosys share has increased by more than 100% this year, and analysts believe the value is capable of even more. Due to positive news, investors can speculate on a rebound with Defence Therapeutics.
Read
Commented by Juliane Zielonka on June 9th, 2023 | 07:30 CEST
Defence Therapeutics, Bayer AG, Palantir Technologies - Networked data revolutionizes the future of production
In the battle against cancer, the Canadian biotech company Defence Therapeutics is focusing on pancreatic cancer cells. They are currently conducting a new study that aims to develop a vaccination against pancreatic cancer. A crucial factor driving this project is the utilization of networked data. Bayer AG is also active in Canada. The Company is partnering with Acuitas to develop new business areas in the field of mRNA-based gene therapy. Palantir Technologies' move to become active in the energy sector is also new. A battery plant in North America serves as a sandbox for this. We provide insight into the latest developments for investors with a growth strategy.
Read
Commented by André Will-Laudien on May 31st, 2023 | 08:30 CEST
Biotech in turnaround mode! BioNTech, Defence Therapeutics, MorphoSys, Formycon - Take a close look at these shares!
Since the major pandemic wave in the biotech sector, most industry players have had to come to terms with normality again. Scolded investors quickly learned their lesson and are now looking warily at an industry that experienced its heyday between 2019 and 2021. Today, it is no longer the small announcements of hope that lead to significant price swings. After months of sell-offs, however, the sector is stabilizing for the first time, and some protagonists can report minor progress. When the sector trend weakens, selection is the trump card. Here are some suggestions.
Read
Commented by Nico Popp on May 22nd, 2023 | 09:55 CEST
Now things can move very quickly: Amazon, Deutsche Bank, Defence Therapeutics
The DAX is close to its all-time high, and the S&P 500 and Nasdaq-100 have also made up considerable ground recently. Although the markets are still marked by uncertainty, there are initial positive signals - the indices speak a clear language, although there are still stragglers. We explain how close the next rally is and which stocks could recover significantly in the short term.
Read
Commented by Stefan Feulner on May 16th, 2023 | 09:30 CEST
Morphosys, Defence Therapeutics, Evotec - A lot of movement in the biotech sector
The biotech sector is on the move. On the one hand, the industry has seen an increase in mergers and acquisitions in recent months. The pharmaceutical giant Pfizer, for example, recently took over Seagan for USD 43 billion. Other companies are likely to follow suit. In addition, many companies were able to break away from their lows of the past months and have further upside potential.
Read